Find a Clinical Trial | American Lung Association

Krascendo 2 (CO45042)

LAM-001 for PH-ILD

Studying inhaled sirolimus in PH-ILD patients

LUNAR-2

LUNG STAAR

The purpose of this research is to offer patients with centrally located early-stage non-small cell lung cancer (NSCLC) who are NOT candidates for surgery the opportunity to receive stereotactic body radiation therapy (SBRT).

MK-1084-004

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.

MK-1084-007

The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

MK-2870-007

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS).

MK-2870-019

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.

MK-6070-002

Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn 1) if gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated and 2) if people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away.

MK-6070-003

The goals of this study are to learn 1) about the safety of combining gocatamig and I-DXd and if people tolerate them together and 2) if people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away.

Next